Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Pharma
2024's top biopharma M&A deals
Despite a return to dealmaking grandeur in 2023, the biopharma industry’s appetite for large-scale mergers and acquisitions was notably more muted in 2024.
Fraiser Kansteiner
,
Zoey Becker
,
Angus Liu
,
Kevin Dunleavy
,
Eric Sagonowsky
Jan 13, 2025 3:00am
Key drugs from Merck, Bayer and Gilead win EMA backing
Dec 13, 2024 10:33am
ICER calls out drugmakers over 'unsupported' price hikes
Dec 12, 2024 2:24pm
Gilead spotlights lenacapivir in plan to hold on to HIV crown
Dec 11, 2024 10:53am
AZ's Enhertu, Akeso's bispecifics win reimbursement in China
Dec 4, 2024 12:52pm
Kelun's Merck-partnered TROP2 ADC snags first nod in China
Nov 27, 2024 10:56am
